Report ID: SQMIG35J2034
Report ID:
SQMIG35J2034 |
Region:
Global |
Published Date: July, 2024
Pages:
242
|
Tables:
63 |
Figures:
75
The pharmaceutical contract development and manufacturing market is anticipated to be dominated by North America in 2022, followed by Europe and Asia-Pacific. The substantial share of this region is primarily linked to expanding generic medicine and biologics demand, CDMO consolidation, rising need for biosimilars due to patent expiry, and rising outsourcing costs. Furthermore, the focus on pharmaceutical and biotechnology research by organisations has made the contract manufacturing business in North America extremely competitive.
However, during the forecast period, Asia-Pacific is expected to have the greatest CAGR. With a revenue share of more than 40%, Asia Pacific dominated the market and is anticipated to expand significantly over the forecast period. This expansion is made possible by an increase in the number of businesses outsourcing work to these nations' emerging economies. Due to their growing production capacities, nations like Singapore, China, and India have recently been recognised as key players in the pharmaceutical sector. The Asian businesses' plenty of cash is to blame for the contract manufacturing industry's monopolistic nature. Significant investments from Asian CMOs are anticipated to spur exponential growth. Due to the presence of well-established multinational players in this area, the Latin American market is predicted to grow significantly over the course of the forecast period. Novartis, Roche, and Pfizer are three significant companies with operations in Brazil. Latin America has the potential to emerge into a major global centre for the creation of pharmaceutical goods. This shift is the result of several factors, including the cheap cost of product creation.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONPharmaceutical Contract Development and Manufacturing Market size was valued at USD 114.36 billion in 2019 and is poised to grow from USD 122.25 billion in 2023 to USD 222.87 billion by 2031, growing at a CAGR of 6.9% in the forecast period (2024-2031).
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35J2034